» Articles » PMID: 39156764

Oncogenic Fusion Protein Interacts with Polypyrimidine Tract Binding Protein 1 to Facilitate Bladder Cancer Proliferation and Metastasis by Regulating MRNA Stability

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2024 Aug 19
PMID 39156764
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric RNAs, distinct from DNA gene fusions, have emerged as promising therapeutic targets with diverse functions in cancer treatment. However, the functional significance and therapeutic potential of most chimeric RNAs remain unclear. Here we identify a novel fusion transcript of solute carrier family 2-member 11 () and macrophage migration inhibitory factor (). In this study, we investigated the upregulation of in The Cancer Genome Atlas cohort and a cohort of patients from Sun Yat-Sen Memorial Hospital. Subsequently, functional investigations demonstrated that enhanced the proliferation, antiapoptotic effects, and metastasis of bladder cancer cells in vitro and in vivo. Mechanistically, the fusion protein encoded by interacted with polypyrimidine tract binding protein 1 () and regulated the mRNA half-lives of Polo Like Kinase 1, Roundabout guidance receptor 1, and phosphoinositide-3-kinase regulatory subunit 3 in BCa cells. Moreover, knockdown abolished the enhanced impact of on biological function and mRNA stability. Furthermore, the expression of mRNA is regulated by CCCTC-binding factor and stabilized through RNA N4-acetylcytidine modification facilitated by N-acetyltransferase 10. Overall, our findings revealed a significant fusion protein orchestrated by the axis that governs mRNA stability during the multistep progression of bladder cancer.

Citing Articles

Integrative multi-omics and machine learning identify a robust signature for discriminating prognosis and therapeutic targets in bladder cancer.

Tan Z, Chen X, Huang Y, Fu S, Li H, Gong C J Cancer. 2025; 16(5):1479-1503.

PMID: 39991573 PMC: 11843231. DOI: 10.7150/jca.105066.

References
1.
Zhou Q, Chen X, He H, Peng S, Zhang Y, Zhang J . WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Theranostics. 2021; 11(10):4809-4824. PMC: 7978315. DOI: 10.7150/thno.55814. View

2.
Gu P, Chen X, Xie R, Han J, Xie W, Wang B . lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Mol Ther. 2017; 25(8):1959-1973. PMC: 5542640. DOI: 10.1016/j.ymthe.2017.04.016. View

3.
Shi X, Singh S, Lin E, Li H . Chimeric RNAs in cancer. Adv Clin Chem. 2021; 100:1-35. DOI: 10.1016/bs.acc.2020.04.001. View

4.
Zhang H, Ye Y, Li M, Ye S, Huang W, Cai T . CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene. 2016; 36(15):2095-2104. DOI: 10.1038/onc.2016.367. View

5.
Babiceanu M, Qin F, Xie Z, Jia Y, Lopez K, Janus N . Recurrent chimeric fusion RNAs in non-cancer tissues and cells. Nucleic Acids Res. 2016; 44(6):2859-72. PMC: 4824105. DOI: 10.1093/nar/gkw032. View